Skip to Content

DUOFILM

Active substance(s): LACTIC ACID / SALICYLIC ACID

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1

NAME OF THE MEDICINAL PRODUCT
Duofilm

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Salicylic acid 16.7% w/w
Lactic acid 15% w/w
Also contains colophony
For the full list of excipients, see section 6.1

3

PHARMACEUTICAL FORM
Solution for topical administration.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Duofilm is indicated for the treatment of warts.

4.2

Posology and method of administration
Adults, the elderly and children aged 2 years and over.
Apply daily to the affected areas only.
Children:
Children under the age of 12 years should be treated under supervision.
Treatment of infants under the age of 2 years is not recommended.
Duofilm should be applied to the wart once daily preferably at bedtime.
Procedure for application:
1. The wart should be soaked in warm water for 5 minutes and dried thoroughly with
a clean towel.
2. The surface of the wart should be rubbed with a nail file, pumice stone, emery
board or coarse washcloth, with care taken not to cause bleeding.
3. A thin layer of Duofilm should be applied directly to the wart. Care should be
taken to avoid the healthy surrounding skin.
4. The solution should be allowed to dry thoroughly. The wart should be covered
with a plaster (dressing) if it is large or if it is on the foot to help penetration of
ingredients.

It is recommended that treatment continues until whichever of the following occurs
first:



Warts have been treated for 12 weeks
The wart is completely cleared and the normal ridgelines of the skin have been
restored.

For warts, clinically visible improvement should occur in 1-2 weeks, but the
maximum effect may be expected after 4-8 weeks.
If warts persist beyond 12 weeks of treatment, the patient should be advised to
consult their pharmacist or doctor.
Consider alternative treatments if warts cover a large area of the body (more than 5
cm2) (see Warnings and Precautions).
Patients should be advised to consult a pharmacist or doctor if skin irritation
develops.
Due to the flammable nature of Duofilm, patients should avoid smoking or being near
an open flame during application and immediately after use.

4.3

Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section
6.1.
Do not use on open wounds, irritated or reddened skin, or any area that is infected.
Duofilm should not be used on the face, anogenital regions, moles, birthmarks,
mucous membranes, warts with hair growing from them, red edges or an unusual
colour. Avoid applying to normal skin.

4.4

Special warnings and precautions for use
Duofilm contains colophony which may cause allergic contact dermatitis.
Duofilm may cause eye irritation. Avoid contact with eyes and other mucous
membranes. In case of accidental contact with the eyes or other mucous membranes,
flush with water for 15 minutes.
Avoid exposure to healthy skin (see Adverse Reactions). Duofilm may cause skin
irritation. If undue skin irritation develops treatment should be discontinued.
Consider alternative treatments if warts cover a large area of the body (more than 5
cm2) due to the potential risk of salicylate toxicity.
Duofilm is not recommended in patients with diabetes, circulatory problems or
peripheral neuropathy except under the supervision of a doctor.
Oral salicylates taken during or immediately after a viral illness have been associated
with Reye’s syndrome and hence there is a theoretical risk with topical salicylates.
Therefore, use is not advised in children or teenagers during or immediately after
chickenpox, influenza, or other viral infections.
It has been reported that salicylates are excreted via breast milk (see Pregnancy and
Lactation).

Patients should be advised not to inhale the vapour.
Keep out of the sight and reach of children.

4.5

Interaction with other medicinal products and other forms of interaction
Topical Duofilm may increase the absorption of other topically applied medicines.
Therefore, concomitant use of Duofilm and other topical medicines on the treated
area should be avoided. As systemic exposure of topically applied Duofilm is low,
interaction with systemically administered medicines is not anticipated.

4.6

Fertility, pregnancy and lactation
Pregnancy
The safety of Duofilm during human pregnancy has not been established. Studies in
animals given salicylic acid orally demonstrated embryo toxicity at high doses (see
Non-Clinical Information).
Duofilm is not recommended during pregnancy.
Lactation
Salicylates are excreted in human milk. Duofilm is not recommended during
lactation.
If used or administered during lactation, care should be taken to avoid contact with
the breast area in order to avoid accidental ingestion by the infant.

4.7

Effects on ability to drive and use machines
None

4.8

Undesirable effects
Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and
by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100
and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000) and
very rare (<1/10,000), including isolated reports.
Clinical Trial Data
Immune system disorders
Common: Rash
Skin and subcutaneous tissue disorders
Very common:
Application site reaction, pruritus, burning sensation, erythema, scaling, dryness
Common: Skin hypertrophy
Post Marketing Data
Immune system disorders

Rare: Application site hypersensitivity including inflammation
Skin and subcutaneous tissue disorders
Rare:
Application site pain and irritation
Application site discoloration/skin discoloration
Exposure to healthy skin can lead to application site blistering and skin exfoliation
(see Warnings and Precautions).
Allergic dermatitis

4.9

Overdose
Symptoms and Signs
In the event of accidental oral ingestion symptoms of salicylate toxicity may occur.
The risk of developing symptoms of salicylate poisoning or salicylism is increased if
Duofilm is used excessively or if it is used for prolonged periods of time. Therefore,
duration of use and recommended frequency compliance is very important.
Treatment
Management should be as clinically indicated.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
ATC Code
Pharmacotherapeutic group: Wart and anti-corn preparations.
ATC code: D11AF
Lactic acid affects the keratinisation process, reducing the hyperkeratosis which is
characteristic of warts. At high concentrations it can cause epidermolysis, leading to
the destruction of the keratotic tissue of the wart and of the causative virus. It also has
antiseptic properties.
Flexible collodion provides a viscous vehicle that allows accurate application of the
active ingredients to the wart. It also forms a film that helps to hydrate and promote
the destruction of wart tissue.
Salicylic acid is keratolytic, producing desquamation by solubilising the intercellular
cement in the stratum corneum resulting in the shedding of skin scales.

5.2

Pharmacokinetic properties
Absorption
Salicylic acid is absorbed through the skin; where detectable, maximum plasma levels
are found 6 to 12 hours after application. Systemic absorption of salicylic acid has
been reported to range from 9% to 25% after topical application of other salicylic
acid-containing preparations. The extent of absorption is variable depending on the

duration of contact and the vehicle. Despite percutaneous absorption, the systemic
exposure is low given the low dose topically administered to small, localised areas of
hyperkeratotic tissue.
Human abdominal skin in a flow-through diffusion system was used to assess the in
vitro percutaneous absorption of lactic acid. At a pH of 3, the amount of radioactivity
detected in the receptor fluid, stratum corneum, epidermis, and dermis was 3.6, 6.3,
6.6, and 13.9%, respectively.
Distribution
Following percutaneous absorption, salicylic acid is distributed in the extracellular
space; approximately half of which is protein bound to albumin.
Metabolism
Salicylates are metabolised in the liver by microsomal enzymes to salicyluric acid and
phenolic glucuronides of salicylic acid. That which is not metabolised is excreted in
the urine as unchanged salicylic acid.
Elimination
Within 24 hours of salicylic acid being absorbed and distributed in the intercellular
space, approximately 95% of the absorbed dose can be recovered in the urine.

5.3

Preclinical safety data
Not applicable.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Flexible Collodion
(Contains pyroxylin, colophony, virgin castor oil, ethanol and ether)

6.2

Incompatibilities
None.

6.3

Shelf life
a) For the product as packaged for sale
3 years
b) After first opening the container
Comply with expiry date

6.4

Special precautions for storage
Do not store above 25°C. Keep away from naked flame.

6.5

Nature and contents of container
Amber screw capped applicator bottle containing 15ml.

6.6

Special precautions for disposal
There are no special instructions for use or handling of Duofilm.

7

MARKETING AUTHORISATION HOLDER
Beecham Group plc
trading as
Stiefel
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 00079/0695

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
14/02/1990

10

DATE OF REVISION OF THE TEXT
21/01/2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide